[Federal Register: August 27, 2003 (Volume 68, Number 166)]
[Rules and Regulations]
[Page 51445-51446]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27au03-5]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
Oral Dosage Form New Animal Drugs; Moxidectin and Praziquantel
Gel
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of a new animal drug application
(NADA) filed by Fort Dodge Animal Health, Division of Wyeth. The NADA
provides for use of a moxidectin and praziquantel oral gel for the
treatment and control of various species of internal parasites in
horses and ponies.
DATES: This rule is effective August 27, 2003.
FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for
Veterinary Medicine (HFV-110), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855; 301-827-7543; e-mail:
mberson@cvm.fda.gov.
SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, Div. of Wyeth, 800
Fifth St. NW., Fort Dodge, IA 50501, filed NADA 141-216 for QUEST PLUS
(moxidectin 2.0%/praziquantel 12.5%) Gel for the treatment and control
of various species of internal parasites in horses and ponies. The NADA
is approved as of May 14, 2003, and part 520 (21 CFR part 520) is
amended by adding new Sec. 520.1453 to reflect the approval. The basis
of approval is discussed in the freedom of information summary.
In accordance with the freedom of information provisions of 21 CFR
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and
effectiveness data and information submitted to support approval of
this application may be seen in the Dockets Management Branch (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for
3 years of marketing exclusivity beginning.
The agency has determined under 21 CFR 25.33(d)(1) that this action
is of a type that does not individually or cumulatively have a
significant effect on the human environment. Therefore,
[[Page 51446]]
neither an environmental assessment nor an environmental impact
statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects in 21 CFR Part 520
Animal drugs.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is
amended as follows:
PART 520-ORAL DOSAGE FORM NEW ANIMAL DRUGS
0
1. The authority citation for 21 CFR part 520 continues to read as
follows:
Authority: 21 U.S.C. 360b.
0
2. Section 520.1453 is added to read as follows:
Sec. 520.1453 Moxidectin and praziquantel gel.
(a) Specifications. Each milliliter of gel contains 20 milligrams
(mg) (2.0 percent) moxidectin and 125 mg (12.5 percent) praziquantel.
(b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
(c) Special considerations. See Sec. 500.25 of this chapter.
(d) Conditions of use in horses and ponies--(1) Amount. Administer
by mouth as a single dose: 0.4 mg moxidectin per kilogram and 2.5 mg
praziquantel per kilogram (2.2 pounds) body weight.
(2) Indications for use. For treatment and control of large
strongyles (Strongylus vulgaris (adults and L4/L5 arterial stages), S.
edentatus (adults and tissue stages), Triodontophorus brevicauda
(adults), T. serratus (adults)); small strongyles (Cyathostomum spp.
(adults), Cyathostomum catinatum (adults), Cylicocyclus spp. (adults),
Cylicostephanus spp. (adults), Gyalocephalus capitatus (adults),
undifferentiated lumenal larvae; encysted cyathostomes (late L3 and L4
mucosal cyathostome larvae)); ascarids (Parascaris equorum (adults and
L4 larval stages)); pinworms (Oxyuris equi (adults and L4 larval
stages)); hairworms (Trichostrongylus axei (adults)); large-mouth
stomach worms (Habronema muscae (adults)); horse stomach bots
(Gasterophilus intestinalis (2nd and 3rd instars) and G. nasalis (3rd
instars)); and tapeworms (Anoplocephala perfoliata (adults)). One dose
also suppresses strongyle egg production for 84 days.
(3) Limitations. For oral use in horses and ponies 6 months of age
and older. Not for use in horses and ponies intended for food.
Dated: August 13, 2003.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 03-21833 Filed 8-26-03; 8:45 am]
BILLING CODE 4160-01-S